InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBC's Annual World Congress Conference in Boston on Aug 6th
Dr. Thomas Kindt, Chief Scientific Officer will present an in-depthpresentation on a Case Study of InNexus' preclinical candidate DXL625 (CD20):A New Platform for Augmenting Antibody Therapeutics for Cancer. Chairman andCEO, Jeff Morhet will also provide a company overview, including informationabout InNexus' unique business strategy, its DXL(TM) technology platform andupcoming company milestones. Investors, venture capitalists, companyexecutives, scientists and other industry leaders will attend the conferences.
InNexus is a drug development company commercializing the next generationof monoclonal antibodies based on its DXL(TM) technology, which improves thepotency of existing antibody products while opening new markets and diseaseapplications. DXL(TM) antibodies utilize unique, novel and patented methodsand technologies of InNexus.
InNexus is headquartered in British Columbia with principal managementbased in Scottsdale, Arizona on the campus of Mayo Clinic and has its ownin-house developmental facilities. These development resources providevalidation of protein and peptide discoveries, enabling InNexus (and itsstrategic partners) to advance novel drug therapeutics and diagnostics. Tolearn more about InNexus, please visit http://www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not acceptresponsibility for the adequacy or accuracy of this news release. This newsrelease may contain assumptions, estimates, and other forward-lookingstatements that involve inherent risks and uncertainties and are subject tofactors, many of which are beyond the Company's control, that may cause actualresults or performance to differ materially from those currently anticipatedin such statements.
SOURCE InNexus Biotechnology Inc.
You May Also Like